Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Alternative Names: Amorfix EP-AD; Disease specific epitope (DSE) monoclonal antibodies; Neurodegenerative disorders monoclonal antibodies - Amorfix Life Sciences; Neurodegenerative disorders vaccines - Amorfix Life Sciences

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Amorfix Life Sciences
  • Developer Amorfix Life Sciences; ProMIS Neurosciences; University of British Columbia
  • Class Diagnostic agents; Vaccines
  • Mechanism of Action Immunomodulators; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Suspended Creutzfeldt-Jakob disease
  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 08 Oct 2015 ProMIS Neurosciences expands exclusive license agreement with the University of British Columbia to gain worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications and enhancements to ProMIS™ technology
  • 14 Jul 2015 Amorfix Life Sciences is now called ProMIS Neurosciences
  • 12 Jan 2015 Research programme: neurodegenerative disorders immunotherapeutics - Amorfix is available for licensing (www.amorfix.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top